Latest News in the pharma Industry

Research & Development

Cell lines and media for difficult to culture tumour types

Cell lines and media for difficult to culture tumour types

22 Feb 2017

Aids R&D initiatives to advance precision medicine.

Read more 
Can yeast rise to the challenge of curing cancer?

Can yeast rise to the challenge of curing cancer?

21 Feb 2017

Modified baker’s yeasts cause an immune response and the production of lymphocyte killers, which detect and eliminate cancerous cells.

Read more 
Innova Biosciences introduces Magnetic Conjugation Kit

Innova Biosciences introduces Magnetic Conjugation Kit

21 Feb 2017

New kit enables covalent conjugation of antibodies and proteins to magnetic particles.

Read more 
New data in Crohn’s disease patients shows similar efficacy and safety profiles for Inflectra and Remicade

New data in Crohn’s disease patients shows similar efficacy and safety profiles for Inflectra and Remicade

20 Feb 2017

Trial data further supports the existing clinical profile of CT-P13 in inflammatory bowel disease.

Read more 
Phase II study supports potential for Genentech’s Tecentriq plus Avastin for people with mRCC

Phase II study supports potential for Genentech’s Tecentriq plus Avastin for people with mRCC

19 Feb 2017

Study showed that people whose disease expressed PD-L1 and were treated with Tecentriq plus Avastin had a 36% reduction in the risk of their disease worsening

Read more 
FDA expands approval of Spiriva Respimat inhalation spray

FDA expands approval of Spiriva Respimat inhalation spray

16 Feb 2017

Steroid-free Spiriva Respimat now approved as asthma treatment for age 6 and older.

Read more 
Valeant's treatment for plaque psoriasis gets FDA thumbs up for Siliq

Valeant's treatment for plaque psoriasis gets FDA thumbs up for Siliq

16 Feb 2017

More than 50% of patients in three clinical studies who used Siliq achieved total skin clearance within a year.

Read more 
EC approves once-daily Olumiant tablets for treatment of adults with active RA

EC approves once-daily Olumiant tablets for treatment of adults with active RA

14 Feb 2017

Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU.

Read more 
Alzheon to present new clinical data and analyses for ALZ-801

Alzheon to present new clinical data and analyses for ALZ-801

14 Feb 2017

The presentations highlight Alzheon’s ‘precision medicine’ approach to drug development for Alzheimer’s disease.

Read more 
Janssen's two-drug combination demonstrates efficacy in maintaining viral suppression

Janssen's two-drug combination demonstrates efficacy in maintaining viral suppression

14 Feb 2017

If approved, this treatment could be the first two-drug regimen for HIV.

Read more 
Ferring backs Foresee's SIF platform for controlled-release formulations

Ferring backs Foresee's SIF platform for controlled-release formulations

13 Feb 2017

Foresee technology can help to develop stable, formulated peptides in solution for controlled-release therapy for 3- and 6-month durations of action after a single injection.

Read more 
Aquarium-to-bedside drug shows promise in small pediatric trial

Aquarium-to-bedside drug shows promise in small pediatric trial

12 Feb 2017

NIH-funded research suggests zebrafish models may be efficient resource for identifying drugs for clinical use.

Read more